Prelude Therapeutics (PRLD) CEO awarded 837,000 long-term stock options

Rhea-AI Filing Summary

Prelude Therapeutics CEO Krishna Vaddi received a large stock option grant. The Form 4 reports an employee stock option to purchase 837,000 shares of Prelude Therapeutics common stock at an exercise price of $2.30 per share, granted on February 4, 2026.

The option expires on February 3, 2036. It vests 25% on February 4, 2027, then 1/48 of the total shares vests monthly until fully vested, as long as Vaddi continues providing services to the company on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vaddi Krishna

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	837,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 837,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vaddi Krishna

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DE 19805

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.3	02/04/2026		A		837,000		(1)	02/03/2036	Common Stock	837,000	$0.00	837,000	D

Explanation of Responses:

1. The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Bryant D. Lim, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Prelude Therapeutics (PRLD) report on this Form 4?

Prelude Therapeutics reported a grant of employee stock options to CEO and director Krishna Vaddi. The grant covers 837,000 options to buy common shares at $2.30 per share, issued on February 4, 2026, under the company’s equity compensation arrangements.

How many Prelude Therapeutics (PRLD) options were granted to CEO Krishna Vaddi?

CEO Krishna Vaddi was granted 837,000 employee stock options. Each option gives the right to purchase one share of Prelude Therapeutics common stock, subject to vesting conditions and continued service requirements described in the Form 4 filing’s explanatory footnote.

What is the exercise price and term of the new Prelude Therapeutics (PRLD) stock options?

The employee stock options have an exercise price of $2.30 per share and expire on February 3, 2036. This gives CEO Krishna Vaddi the right to buy Prelude Therapeutics common stock at that price during the option term, once vested.

How do the Prelude Therapeutics (PRLD) options granted to the CEO vest over time?

The options vest 25% of the total shares on February 4, 2027. The remaining 75% then vests in equal monthly installments of 1/48 of the total shares, provided Krishna Vaddi continues to provide services to Prelude Therapeutics on each vesting date.

What is Krishna Vaddi’s role at Prelude Therapeutics (PRLD) according to this Form 4?

According to the Form 4, Krishna Vaddi serves as both a director and an officer of Prelude Therapeutics, with the officer title of CEO. The reported transaction reflects an equity award tied to his leadership and ongoing service to the company.

Are the newly granted Prelude Therapeutics (PRLD) options held directly or indirectly?

The Form 4 identifies the 837,000 employee stock options as directly owned. The ownership form is marked as “D” for direct, with no indication in the footnotes that another entity or person holds voting or investment authority over these derivative securities.